Cost Effectiveness of Screening

A new study shows a “modest mortality” reduction for women of average risk, screened annually by the CA-125. The study tested women annually for the CA-125 blood marker; if those results were abnormal women were referred for a transvaginal ultrasound. The study concluded that a better test than the CA-125 is needed to make this type of screening cost effective.

In the past, other studies have not shown screening for ovarian cancer to save women’s lives.

See the abstract here